- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT02183337
Bioavailability of BI 1356 With and Without Co-administration of Pioglitazone and the Bioavailability of Pioglitazone With and Without Coadministration of BI 1356 in Healthy Male and Female Volunteers
4. juli 2014 oppdatert av: Boehringer Ingelheim
Relative Bioavailability of Both BI 1356 and Pioglitazone After Co-administration Compared to the Bioavailability of Multiple Oral Doses of BI 1356 10 mg qd Alone and Pioglitazone 45 mg qd Alone in Healthy Male and Female Volunteers (an Open Label, Randomised, Multiple-dose, Two-way Crossover Study)
Study to investigate the bioavailability of BI 1356 with and without co-administration of pioglitazone and the bioavailability of pioglitazone with and without coadministration of BI 1356
Studieoversikt
Status
Fullført
Forhold
Intervensjon / Behandling
Studietype
Intervensjonell
Registrering (Faktiske)
20
Fase
- Fase 1
Deltakelseskriterier
Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
18 år til 65 år (Voksen, Eldre voksen)
Tar imot friske frivillige
Ja
Kjønn som er kvalifisert for studier
Alle
Beskrivelse
Inclusion Criteria:
- Healthy females and males according to the following criteria: Based upon a complete medical history, including the physical examination, vital signs (Blood Pressure (BP), Pulse Rate (PR)), 12-lead Electrocardiogram (ECG), clinical laboratory tests
- Age ≥18 and Age ≤65 years
- BMI ≥18.5 and BMI ≤29.9 kg/m2 (Body Mass Index)
- Signed and dated written informed consent prior to admission to the study in accordance with Good Clinical Practice (GCP) and the local legislation
Exclusion Criteria:
- Any finding of the medical examination (including BP, PR and ECG) deviating from normal and of clinical relevance
- Any evidence of a clinically relevant concomitant disease
- Gastrointestinal, hepatic, renal, respiratory, cardiovascular, metabolic, immunological or hormonal disorders
- Surgery of the gastrointestinal tract (except appendectomy)
- Diseases of the central nervous system (such as epilepsy) or psychiatric disorders or neurological disorders
- History of relevant orthostatic hypotension, fainting spells or blackouts
- Chronic or relevant acute infections (e.g. HIV)
- History of relevant allergy/hypersensitivity (including allergy to drug or its excipients)
- Intake of drugs with a long half-life (> 24 hours) within at least one month or less than 10 half-lives of the respective drug prior to administration or during the trial
- Use of drugs which might reasonably influence the results of the trial or that prolong the QT/QTc interval based on the knowledge at the time of protocol preparation within 10 days prior to administration or during the trial
- Participation in another trial with an investigational drug within two months prior to administration or during the trial
- Smoker (> 10 cigarettes or > 3 cigars or > 3 pipes/day)
- Inability to refrain from smoking on trial days
- Alcohol abuse (more than 60 g/day)
- Drug abuse
- Blood donation (more than 100 mL within four weeks prior to administration or during the trial)
- Excessive physical activities (within one week prior to administration or during the trial)
- Any laboratory value outside the reference range that is of clinical relevance
- Inability to comply with dietary regimen of trial site
- A marked baseline prolongation of QT/QTc interval (e.g., repeated demonstration of a QTc interval >450 ms)
- A history of additional risk factors for Torsade de Pointes (TdP) (e.g., heart failure, hypokalemia, family history of Long QT Syndrome)
For male subjects:
- Not willing to use adequate contraception (condom use plus another form of contraception e.g. spermicide, oral contraceptive taken by female partner, sterilisation, IUD [intrauterine device]) during the whole study period from the time of the first intake of study drug until one month after the last intake
For female subjects:
- Pregnancy or planning to become pregnant within 2 months of study completion
- Positive pregnancy test
- Are not willing or are unable to use a reliable method of contraception (such as implants, injectibles and combined oral contraceptives, sterilisation, IUD, double barrier method) for at least 3 months prior to participation in the trial, during and up to 2 months after completion/termination of the trial
- Chronic use of oral contraception or hormone replacement containing ethinyl estradiol as the only method of contraception
- Lactation period
Studieplan
Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Behandling
- Tildeling: Randomisert
- Intervensjonsmodell: Crossover-oppdrag
- Masking: Ingen (Open Label)
Våpen og intervensjoner
Deltakergruppe / Arm |
Intervensjon / Behandling |
---|---|
Eksperimentell: BI 1356
Treatment sequence AB_C or C_AB
|
|
Aktiv komparator: Pioglitazone
Treatment sequence AB_C or C_AB
|
Hva måler studien?
Primære resultatmål
Resultatmål |
Tidsramme |
---|---|
AUCτ,ss (area under the concentration-time curve of the analyte in plasma at steady state over a uniform dosing interval τ)
Tidsramme: up to 21 days
|
up to 21 days
|
Cmax,ss (maximum measured concentration of the analyte in plasma at steady state over a uniform dosing interval τ)
Tidsramme: up to 21 days
|
up to 21 days
|
Sekundære resultatmål
Resultatmål |
Tidsramme |
---|---|
tmax,ss (time from last dosing to maximum concentration of the analyte in plasma at steady state)
Tidsramme: up to 21 days
|
up to 21 days
|
C24,ss (concentration of the analyte in plasma at steady state after administration of the last dose at the end of the dosing interval)
Tidsramme: up to 21 days
|
up to 21 days
|
λz,ss (terminal rate constant in plasma at steady state)
Tidsramme: up to 21 days
|
up to 21 days
|
t1/2,ss (terminal half-life of the analyte in plasma at steady state)
Tidsramme: up to 21 days
|
up to 21 days
|
MRTpo,ss (mean residence time of the analyte in the body at steady state after oral administration)
Tidsramme: up to 21 days
|
up to 21 days
|
CL/F,ss (apparent clearance of the analyte in the plasma after extravascular administration at steady state)
Tidsramme: up to 21 days
|
up to 21 days
|
Vz/F,ss (apparent volume of distribution during the terminal phase λz at steady state following extravascular administration)
Tidsramme: up to 21 days
|
up to 21 days
|
Changes in physical examination (including body weight)
Tidsramme: up to 27 days after last administration of study medication
|
up to 27 days after last administration of study medication
|
Changes in Vital signs (Blood pressure (BP), Pulse Rate (PR)
Tidsramme: up to 27 days after last administration of study medication
|
up to 27 days after last administration of study medication
|
Changes in 12-lead ECG (electrocardiogram)
Tidsramme: up to 27 days after last administration of study medication
|
up to 27 days after last administration of study medication
|
Changes in clinical laboratory values
Tidsramme: up to 27 days after last administration of study medication
|
up to 27 days after last administration of study medication
|
Number of patients with adverse events
Tidsramme: up to 27 days after last administration of study medication
|
up to 27 days after last administration of study medication
|
Assessment of tolerability by investigator on a 4-point scale
Tidsramme: up to 27 days after last administration of study medication
|
up to 27 days after last administration of study medication
|
Samarbeidspartnere og etterforskere
Det er her du vil finne personer og organisasjoner som er involvert i denne studien.
Sponsor
Publikasjoner og nyttige lenker
Den som er ansvarlig for å legge inn informasjon om studien leverer frivillig disse publikasjonene. Disse kan handle om alt relatert til studiet.
Hjelpsomme linker
Studierekorddatoer
Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.
Studer hoveddatoer
Studiestart
1. februar 2007
Primær fullføring (Faktiske)
1. april 2007
Datoer for studieregistrering
Først innsendt
4. juli 2014
Først innsendt som oppfylte QC-kriteriene
4. juli 2014
Først lagt ut (Anslag)
8. juli 2014
Oppdateringer av studieposter
Sist oppdatering lagt ut (Anslag)
8. juli 2014
Siste oppdatering sendt inn som oppfylte QC-kriteriene
4. juli 2014
Sist bekreftet
1. juli 2014
Mer informasjon
Begreper knyttet til denne studien
Ytterligere relevante MeSH-vilkår
Andre studie-ID-numre
- 1218.13
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .
Kliniske studier på Sunn
-
Universidade do PortoFundação para a Ciência e a TecnologiaRekrutteringHealthy People-programmerPortugal
-
VA Office of Research and DevelopmentFullført
-
Universidad Católica del MauleFullført
-
University of MiamiJames and Esther King Biomedical Research ProgramAvsluttetHealthy Lifetime Ikke-røykereForente stater
-
Fundació Institut de Recerca de l'Hospital de la...FullførtHealthy People-programmerSpania
-
University of LeicesterNational Institute for Health Research, United KingdomFullførtPasienter med hjertesvikt og bevart ejeksjonsfraksjon - HFpEF | Pasienter med hjertesvikt med redusert ejeksjonsfraksjon - HFrEF | Healthy Controls Group - alders- og kjønnsmatchet
-
University Hospital, GrenobleUniversity Hospital, Clermont-Ferrand; Grenoble Institut des NeurosciencesAvsluttetParkinsons sykdom | Healthy Controls Group - alders- og kjønnsmatchetFrankrike
Kliniske studier på BI 1356
-
Boehringer IngelheimFullført
-
Boehringer IngelheimFullførtDiabetes mellitus, type 2Canada, Kroatia, Estland, Frankrike, Tyskland, India, Litauen, Mexico, Nederland, Romania, Den russiske føderasjonen, Sverige, Tunisia, Ukraina
-
Boehringer IngelheimFullført
-
Boehringer IngelheimFullførtDiabetes mellitus, type 2
-
Boehringer IngelheimEli Lilly and CompanyFullførtDiabetes mellitus, type 2Forente stater, Argentina, Australia, Canada, El Salvador, Tyskland, Italia, Portugal, Den russiske føderasjonen, Spania, Ukraina
-
Boehringer IngelheimFullførtDiabetes mellitus, type 2Forente stater, Australia, Canada, Tsjekkisk Republikk, Den russiske føderasjonen, Ukraina
-
Boehringer IngelheimFullført